-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Timber Pharmaceuticals (NYSE:TMBR) Shares Down 6%
Timber Pharmaceuticals (NYSE:TMBR) Shares Down 6%
Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating)'s share price fell 6% during mid-day trading on Monday . The stock traded as low as $0.11 and last traded at $0.11. 4,525,740 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 5,556,676 shares. The stock had previously closed at $0.12.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lowered their price objective on Timber Pharmaceuticals from $1.50 to $1.00 and set a "buy" rating on the stock in a report on Monday, August 29th.
Get Timber Pharmaceuticals alerts:Timber Pharmaceuticals Price Performance
The stock has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.25. The stock has a market capitalization of $14.57 million, a price-to-earnings ratio of -0.33 and a beta of 0.27. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 1.30.
Timber Pharmaceuticals (NYSE:TMBR – Get Rating) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.05). Timber Pharmaceuticals had a negative return on equity of 228.75% and a negative net margin of 1,274.17%. As a group, equities research analysts forecast that Timber Pharmaceuticals, Inc. will post -0.17 earnings per share for the current year.Institutional Trading of Timber Pharmaceuticals
An institutional investor recently raised its position in Timber Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) by 37.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 871,237 shares of the company's stock after buying an additional 238,663 shares during the quarter. Renaissance Technologies LLC owned approximately 1.36% of Timber Pharmaceuticals worth $335,000 at the end of the most recent reporting period. 5.78% of the stock is currently owned by institutional investors and hedge funds.
Timber Pharmaceuticals Company Profile
(Get Rating)
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
Featured Articles
- Get a free copy of the StockNews.com research report on Timber Pharmaceuticals (TMBR)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
Receive News & Ratings for Timber Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timber Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating)'s share price fell 6% during mid-day trading on Monday . The stock traded as low as $0.11 and last traded at $0.11. 4,525,740 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 5,556,676 shares. The stock had previously closed at $0.12.
週一午盤，Wood PharmPharmticals Inc.(紐約證券交易所代碼：TMBR-GET Rating)股價下跌6%。該股盤中一度跌至0.11美元，最新報0.11美元。午盤交易中，有4,525,740股股票易手，較5,556,676股的平均成交量下降19%。該股此前收盤報0.12美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, HC Wainwright lowered their price objective on Timber Pharmaceuticals from $1.50 to $1.00 and set a "buy" rating on the stock in a report on Monday, August 29th.
另外，HC Wainwright在8月29日(星期一)的一份報告中將Timber PharmPharmticals的目標價從1.50美元下調至1.00美元，並對該股設定了“買入”評級。
Timber Pharmaceuticals Price Performance
木材藥品價格表現
The stock has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.25. The stock has a market capitalization of $14.57 million, a price-to-earnings ratio of -0.33 and a beta of 0.27. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 1.30.
該股的50日移動均線為0.16美元，200日移動均線為0.25美元。該股市值為1,457萬美元，市盈率為-0.33，貝塔係數為0.27。該公司的流動比率為1.41，速動比率為1.41，債務權益比率為1.30。
Institutional Trading of Timber Pharmaceuticals
木材藥品的制度性交易
An institutional investor recently raised its position in Timber Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) by 37.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 871,237 shares of the company's stock after buying an additional 238,663 shares during the quarter. Renaissance Technologies LLC owned approximately 1.36% of Timber Pharmaceuticals worth $335,000 at the end of the most recent reporting period. 5.78% of the stock is currently owned by institutional investors and hedge funds.
一家機構投資者最近提高了對Timber PharmPharmticals股票的頭寸。復興科技有限責任公司在提交給美國證券交易委員會的最新Form 13F文件中稱，該公司第一季度增持了37.7%的Timber PharmPharmticals，Inc.股票。該基金在本季度額外購買了238,663股後，持有該公司871,237股股票。在最近一次報告期結束時，復興技術公司擁有木材製藥公司約1.36%的股份，價值33.5萬美元。5.78%的股票目前由機構投資者和對衝基金持有。
Timber Pharmaceuticals Company Profile
木材製藥公司簡介
(Get Rating)
(獲取評級)
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
Wood PharmPharmticals LLC是一家臨牀階段的生物製藥公司，致力於孤兒皮膚病治療藥物的開發和商業化。該公司的主要候選產品包括TMB-001和TMB-002，TMB-001是異維A酸的專利局部製劑，已完成2b階段臨牀試驗，用於治療中到重度CI，這是一組罕見的遺傳性角化性疾病；以及TMB-002，是雷帕黴素的專利局部製劑，用於治療結節性硬化症中的面部血管纖維瘤，這是一種導致多器官錯構瘤生長的多系統遺傳疾病。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Timber Pharmaceuticals (TMBR)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- 免費獲取StockNews.com關於木材製藥的研究報告(TMBR)
- Lucid看起來像是電動汽車的贏家
- 仍然愛着它：投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎？
- 自動區重新進入拉力賽模式，新高在望
- Upwork股價跌入便宜貨領域
Receive News & Ratings for Timber Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timber Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《木材醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對木材製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧